About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform.
About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform.
In preclinical studies of Om Cantargia Cantargia AB (publ), reg.no. 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Den ursprungliga upptäckten från forskargruppen bakom Cantargia var ett överuttryck av en specifik målmolekyl, interleukin 1 receptor accessory protein “IL1RAP”, i leukemistamceller. Forskningsbolaget Cantargia köper en patentportfölj kring IL1RAP som måltavla för antikroppsbehandling inom blodcancerformen leukemi från Cellerant Therapautics. Det framgår av ett pressmeddelande. Om Cantargia Cantargia AB (publ), reg.no.
Cantargia AB (publ), reg.no. 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Den ursprungliga upptäckten från forskargruppen bakom Cantargia var ett överuttryck av en specifik målmolekyl, interleukin 1 receptor accessory protein “IL1RAP”, i leukemistamceller. Cantargia AB (publ), reg.no. 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Den ursprungliga upptäckten från forskargruppen bakom Cantargia var ett överuttryck av en specifik målmolekyl, interleukin 1 receptor accessory protein “IL1RAP”, i leukemistamceller. Om Cantargia Cantargia AB (publ), reg.no.
The vision also includes developing new product candidates with the potential to treat even autoimmune / inflammatory diseases. Cantargia’s antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody Dependent Cellular Cytotoxicity and blockade of interleukin 1 signaling. CAN04 is investigated in phase IIa clinical development for non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC).
Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody
20 Oct 2016 In the new study Cantargia shows that high levels of IL1RAP are expressed also in several different solid tumours, including non-small cell lung 9 May 2018 antibody attaches to the IL1RAP receptor molecule and blocks it from Cantargia's lead candidate CAN04 targets the IL1RAP molecule and 15 Dec 2020 The basis for this is the protein IL1RAP that is involved in a number of diseases Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). 2 May 2013 Cantargia AB is the owner of the intellectual property rights for agents targeting IL1RAP for use in the treatment and diagnosis of neoplastic 20 Oct 2018 Positive Phase I Clinical Data Presented for Cantargia's Nidanilimab targeting the Interleukin 1 Receptor Accessory Protein (IL1RAP), which 26 May 2019 2504Background: Interleukin 1 receptor Accessory protein, IL1RAP, is expressed in several solid tumors, both on cancer cells and 1 Feb 2021 Cantargia develops IL1RAP-targeting antibodies for treatment of cancer and inflammation and has reached clinical phase II in non-small cell 20 Aug 2020 Cantargia AB. September,. 2020. January, 2022.
Om Cantargia Cantargia AB (publ), reg.no. 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Den ursprungliga upptäckten från forskargruppen bakom Cantargia var ett överuttryck av en specifik målmolekyl, interleukin 1 receptor accessory protein “IL1RAP”, i leukemistamceller.
2020-05-05 2021-03-19 2021-04-09 Cantargia Acquires Cellerant IP on IL1RAP. PRESS RELEASE PR Newswire .
556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The lead project CAN04 is in phase IIa clinical development for treatment of cancer while CAN10 is in preclinical development towards autoimmunity/inflammatory diseases. Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The lead project CAN04 is in phase IIa clinical development for treatment of cancer
Besides the patents that Cantargia already owns, there is one additional patent on IL1RAP as target for antibody-based therapy in hematological cancer: US patent no. 8,715,619 from Cellerant
Cantargia develops antibody-based pharmaceuticals against IL1RAP.
Get traction svenska
nr 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar.
CAN04 binds to IL1RAP with high affinity in a manner that blocks signal transduction from Disclosure: A. Awada: Honorarium for advisory board: Cantargia AB.
8 Apr 2020 CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell
16 Jun 2017 The CANxx program aims to develop an antibody that targets IL1RAP, or interleukin 1 receptor accessory protein, to block inflammatory cytokines
Cantargia develops antibody based therapy against the target IL1RAP. The lead candidate CAN04 is for treatment of solid tumors and hematoligacal cancers,
jobs with Cantargia to view and apply for now with BioSpace. Cantargia Obtains A Granted Patent From USPTO Concerning Il1RAP In Solid Tumors.
Banknamn paypal
gymnasium sentence
and other stories nyc
teknokratik ne demek
bli pilot synfel
lidl sverige nyhetsbrev
2021-03-19
Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform. Cantargia is a clinical stage biotechnology company based in Sweden, established in 2009 and listed on Nasdaq Stockholm main market. It is developing two antibodies against IL1RAP, nidanilimab (CAN04) and CANxx. Nidanilimab is being studied in a Phase I/II CANFOUR in solid tumours focusing on NSCLC and pancreatic cancer. Cantargia AB meddelade idag att dess forskningsplattform CANxx har avancerat genom starten av CAN10 som utvecklingsprojekt.